Show simple item record

dc.contributor.authorPoon, Michael TCen
dc.contributor.authorRea, Catherineen
dc.contributor.authorKolias, Angelosen
dc.contributor.authorBrennan, Paul Men
dc.contributor.authorBritish Neurosurgical Trainee Research Collaborative (BNTRC),en
dc.date.accessioned2019-01-03T00:30:18Z
dc.date.available2019-01-03T00:30:18Z
dc.date.issued2021-04en
dc.identifier.issn0897-7151
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/287485
dc.description.abstractWe aim to describe the outcomes following CSDH management in a large cohort of patients on antithrombotic drugs, either antiplatelets or anticoagulants, at presentation and to inform clinical decision making on the timing of surgery and recommencement of these drugs. We used data from a previous UK-based multicenter prospective cohort study. Outcomes included recurrence within 60 days, functional outcome at discharge, and thromboembolic event during hospital stay. We performed Cox regression on recurrence and multiple logistic regression on functional outcome. There were 817 patients included in the analysis, of which 353 (43.2%) were on an antithrombotic drug at presentation. We observed a gradual reduction in risk of recurrence for patients during the 6 weeks post CSDH surgery. Neither antiplatelet nor anticoagulant drug use influenced risk of CSDH recurrence (hazard ratio 0.93; 95% confidence interval [CI] 0.58-1.48; p=0.76) or persistent/worse functional impairment (odds ratio 1.08; 95% CI 0.76-1.55; p=0.66). Delaying surgery after cessation of antiplatelet drug did not affect risk of bleed recurrence. There were 15 in-hospital thromboembolic events recorded. Events were more common in the group pre-treated with antithrombotic drugs (3.3%) compared with the non-antithrombotic group (0.9%). Patients on an antithrombotic drug pre-operatively were at higher risk of thromboembolic events with no excess risk of bleed recurrence or worse functional outcome after CSDH drainage. The data did not support delaying surgery in patients on antithrombotic therapy. In the absence of a randomized controlled trial, early surgery and early antithrombotic recommencement should be considered in those at high risk of thromboembolic events.
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.publisherMary Ann Liebert
dc.subjectBritish Neurosurgical Trainee Research Collaborative (BNTRC)en
dc.titleInfluence of Antiplatelet and Anticoagulant Drug Use on Outcomes after Chronic Subdural Hematoma Drainage.en
dc.typeArticle
prism.endingPage1184
prism.issueIdentifier8en
prism.publicationDate2021en
prism.publicationNameJournal of neurotraumaen
prism.startingPage1177
prism.volume38en
dc.identifier.doi10.17863/CAM.34790
dcterms.dateAccepted2018-11-20en
rioxxterms.versionofrecord10.1089/neu.2018.6080en
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2021-04en
dc.contributor.orcidPoon, Michael TC [0000-0002-0053-2184]
dc.contributor.orcidKolias, Angelos [0000-0003-3992-0587]
dc.identifier.eissn1557-9042
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (G0601025)
pubs.funder-project-idMRC (G1002277)
pubs.funder-project-idMRC (G0600986)
pubs.funder-project-idMRC (G9439390)
pubs.funder-project-idNIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (HTA/12/35/57)
pubs.funder-project-idNIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (HTA/13/15/02)
pubs.funder-project-idTCC (NIHR-RP-R3-12-013)
rioxxterms.freetoread.startdate2019-12-10


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record